Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), confirmed either through a tissue sample or medical imaging
- People aged between 18 and 80 years old
- People who have between 1 and 3 liver tumours
- People whose tumour is at least 4 cm in size (or, if there are 2–3 tumours, their combined size is at least 4 cm)
- People who have enough healthy liver tissue remaining (confirmed by medical measurement)
- People whose liver function falls within a certain range, measured by scoring systems used by doctors (confirm with trial site)
- People whose liver cancer is classified at a certain stage using a standard staging system used by liver cancer specialists (confirm with trial site)
- People who are not eligible for, or have chosen not to have, surgery to remove the tumour or a liver transplant
- People whose recent blood test results (taken within 2 weeks before registering) meet specific levels for white blood cells, platelets, liver enzymes, and kidney function (confirm with trial site for exact values)
Who may not be able to join:
- People whose cancer has spread outside the liver, such as to lymph nodes or other parts of the body
- People whose cancer has grown into major blood vessels in the liver
- People who have certain abnormal connections between blood vessels in the liver (confirm with trial site)
- People who have a history of another cancer
- People who have previously received a treatment called SIRT (a type of radiation therapy delivered to the liver)
- People who have taken the drug Sorafenib within the last 8 weeks
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael J. Eble, Professor Dr. med., University medical center RWTH Aachen
Phone: +49241 80-8926
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1-year local control rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.